Advances and Applications of Multiplexed Diagnostic Technologies in Autoimmune Diseases
The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Abstract
There is a rapid proliferation of new technologies to identify an ever increasing spectrum of autoantibodies in diverse medical conditions that range from organ-specific autoimmune diseases to systemic rheumatic diseases. Although many laboratories have adopted diagnostic platforms, such as enzyme linked immunoassays (ELISAs), to improve turn around times and meet budget constraints, the prevailing evidence is that the rapid adoption of new technologies is not attended by an appropriate balance of assay sensitivity and specificity. Emerging diagnostic technologies include addressable laser bead immunoassays, microarrays in microfluidics platforms and nanobarcode particles. Although these technologies provide advantages of high-throughput, multiplexed autoantibody assays that can be coupled to other disease specific biomarkers (ie, cytokines, single nucleotide polymorphisms) there is a clear need for standardization and internal validation before they are adopted into the clinical diagnostic laboratory.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The advantages of these multiplex assays are that they are fast, relatively cheap and high-throughput [60], [70].”
From Laboratory evaluation of anti-dsDNA antibodies. (2022) · cites this paper as [70]
Citations
Cites
Sherer, Y., Gorstein, A., Fritzler, M. J., & Shoenfeld, Y. (2004) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2004.07.002 · Cited by 578
Self-citationTroyanov, Y., Targoff, I. N., Tremblay, J.-L., Goulet, J.-R., Raymond, Y., & Senécal, J.-L. (2005) · Medicine · doi:10.1097/01.md.0000173991.74008.b0 · Cited by 506
Hendrick, J. P., Wolin, S. L., Rinke, J., Lerner, M. R., & Steitz, J. A. (1981) · Molecular and Cellular Biology · doi:10.1128/mcb.1.12.1138 · Cited by 400
Nanodiagnostics: application of nanotechnology in molecular diagnostics
Jain, K. (2003) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.3.2.153 · Cited by 372
The basis of autoimmunity: Part I mechanisms of aberrant self-recognition
Theofilopoulos, A. N. (1995) · Immunology Today · doi:10.1016/0167-5699(95)80095-6 · Cited by 240
RUTJES, S. A., VREE EGBERTS, W. T. M., JONGEN, P., VAN DEN HOOGEN, F., PRUIJN, G. J. M., & VAN VENROOIJ, W. J. (2003) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.1997.4081308.x · Cited by 201
Biomarkers in systemic lupus erythematosus: II. Markers of disease activity
Illei, G. G., Tackey, E., Lapteva, L., & Lipsky, P. E. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20345 · Cited by 159
Microarrays – status and prospects
Venkatasubbarao, S. (2004) · Trends in biotechnology · doi:10.1016/j.tibtech.2004.10.008 · Cited by 134
Illei, G. G., Tackey, E., Lapteva, L., & Lipsky, P. E. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20344 · Cited by 130
The importance of tissue substrate in the SS‐A/Ro antigen‐antibody system
HARMON, C. E., Deng, J., Peebles, C., & Tan, E. M. (1984) · Arthritis & Rheumatism · doi:10.1002/art.1780270207 · Cited by 126
Rapid molecular theranostics in infectious diseases.
Picard, F., & Bergeron, M. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(02)02497-2 · Cited by 119
SHOVMAN, O., GILBURD, B., BARZILAI, O., SHINAR, E., LARIDA, B., ZANDMAN‐GODDARD, G., BINDER, S. R., & SHOENFELD, Y. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1313.120 · Cited by 114
Epitope spreading in systemic lupus erythematosus: Identification of triggering peptide sequences
Monneaux, F., & Muller, S. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10263 · Cited by 106
Wiik, A. S., Gordon, T. P., Kavanaugh, A. F., Lahita, R. G., Reeves, W., Van Venrooij, W. J., Wilson, M. R., Fritzler, M., & The IUIS/WHO/AF/CDC Committee for the Standardization of Autoantibodies in Rheumatic and Related Diseases (2004) · Arthritis Care & Research · doi:10.1002/art.20229 · Cited by 87
Self-citationShared Early Autoantibody Recognition Events in the Development of Anti‐Sm B/B' in Human Lupus
Arbuckle, Reichlin, Harley, & James (1999) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.1999.00640.x · Cited by 84
Multiplexed AtheNA multi-lyte immunoassay for ANA screening in autoimmune diseases
Shovman, O., Gilburd, B., Zandman-Goddard, G., Yehiely, A., Langevitz, P., & Shoenfeld, Y. (2005) · Autoimmunity · doi:10.1080/08916930400022707 · Cited by 75
Epitope spreading within lupus-associated ribonucleoprotein antigens
Deshmukh, U. S., Bagavant, H., Lewis, J. E., Gaskin, F., & Fu, S. M. (2005) · Clinical Immunology · doi:10.1016/j.clim.2005.07.002 · Cited by 63
The use and abuse of commercial kits used to detect autoantibodies.
Fritzler, M. J., Wiik, A., Fritzler, M. L., & Barr, S. G. (2003) · Arthritis Research · doi:10.1186/ar782 · Cited by 62
Self-citationRouquette, M., Desgruelles, M., & Laroche, P. (2003) · American Journal of Clinical Pathology · doi:10.1309/gjhk-0d24-yddx-w0nf · Cited by 61
Gilburd, B., Abu‐Shakra, M., Shoenfeld, Y., Giordano, A., Bartoloni, E., Monache, F. D., & Gerli, R. (2004) · Journal of Immunology Research · doi:10.1080/10446670410001670490 · Cited by 60
Mechanisms of Autoantibody Diversification to SLE‐Related Autoantigens
Deshmukh, U. S., Gaskin, F., Lewis, J. E., Kannapell, C. C., & Fu, S. M. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb06036.x · Cited by 59
Meheus, L., van Venrooij, W. J., Wiik, A. C., Charles, P. J., Tzioufas, A. G., Meyer, O., Steiner, G. E., Gianola, D. S., Bombardieri, S., Union, A., et al. (1999) · PubMed · Cited by 54
Fritzler, M. J., Hanson, C., Miller, J., & Eystathioy, T. (2002) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.10026 · Cited by 31
Self-citationFrom animal models to human genetics: research on the induction and pathogenicity of autoantibodies
Conrad, K., Bachmann, M. P., Matsuura, E., & Shoenfeld, Y. (2004) · Autoimmunity Reviews · doi:10.1016/j.autrev.2004.10.001 · Cited by 30
Miyachi, K., Hirano, Y., Horigome, T., Mimori, T., Miyakawa, H., Onozuka, Y., Shibata, M., Hirakata, M., Suwa, A., Hosaka, H., et al. (2004) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2004.02456.x · Cited by 29
Self-citationHarley, J. B., & James, J. A. (1995) · PubMed · Cited by 29
Autoantibodies to nonhistone nuclear antigens and their clinical significance
Nakamura, R. M., & Tan, E. M. (1983) · Human Pathology · doi:10.1016/s0046-8177(83)80283-4 · Cited by 24
van der Linden, M. W., Westendorp, R. G. J., Zidane, M., Meheus, L., & Huizinga, T. W. J. (2001) · PubMed · Cited by 21
Use of Nanobarcodes® Particles in Bioassays
Freeman, R. G., Raju, P. A., Norton, S. M., Walton, I. D., Smith, P. C., He, L., Natan, M. J., Sha, M. Y., & Penn, S. G. (2005) · Humana Press eBooks · doi:10.1385/1-59259-901-x:073 · Cited by 17
Research works printed but not linked: 8
- Craft J, 1987, J Rheumatol, 14, 106
- Harley JB, 1995, J Lab Clin Med, 126, 509
- 2000, Med Device Technol, 11, 33
- Meheus L, 1999, Clin Exp Rheumatol, 17, 205
- van der Linden MW, 2001, J Rheumatol, 28, 284
- Freeman RG, 2005, Methods Mol Biol, 303, 73
- 10.1309/gjhk0d24yddxw0nf · doi:10.1309/gjhk0d24yddxw0nf · Paper page
- Kniss R., 1998, Amer Lab, 30, 40
Cited by
Koenig, M., Joyal, F., Fritzler, M. J., Roussin, A., Abrahamowicz, M., Boire, G., Goulet, J., Rich, É., Grodzicky, T., Raymond, Y., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.24038 · Cited by 615
Self-citationAutoantibodies in systemic sclerosis
Mehra, S., Walker, J., Patterson, K., & Fritzler, M. J. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.05.011 · Cited by 252
“At the outset, it is important to understand that the strength and validity of autoantibody associations with clinical features of SSc can vary according to the diagnostic techniques being used, but this variation is compounded by demographic, geographic, environmental and genetic factors [13,14].”
BackgroundSelf-citationMahler, M., Meroni, P.-L., Bossuyt, X., & Fritzler, M. J. (2014) · Journal of Immunology Research · doi:10.1155/2014/315179 · Cited by 203
“The IIF assay on HEp-2 cells has been replaced in many laboratories since the development of ANA screening assays based on ELISA and automated, high throughput multiplex assays using addressable laser bead and other array technologies for the detection of specific ANA [9, 10].”
BackgroundMethodSelf-citationKoenig, M., Fritzler, M. J., Targoff, I. N., Troyanov, Y., & Senécal, J.-L. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2276 · Cited by 199
“The assay was performed at the Advanced Diagnostics Laboratory of the University of Calgary.”
BackgroundMethodInfluentialSelf-citationFu, Q., Schoenhoff, F., Savage, W. J., Zhang, P., & Eyk, J. E. V. (2010) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200900217 · Cited by 108
Metadata
- Authors
- Fritzler, M.
- Affiliations
- Department of Medicine, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada,
- Venue
- Lupus
- Publisher
- SAGE Publications
- Published
- 2006-07
- Volume
- 15
- Issue
- 7
- Pages
- 422-427
- ISSN
- 0961-2033 (ISSN-L)
- 1477-0962
- OpenAlex
- W1989885720
- Cited by
- 78
- References
- 30
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 3 · 2018: 5 · 2017: 1 · 2016: 5 · 2015: 3 · 2014: 4 · 2013: 6 · 2012: 4
- FWCI
- 0.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Lupus (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced Biosensing Techniques and Applications
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- autoantibodies, multiplex immunoassay, autoimmune disease, rheumatic diseases, assay sensitivity and specificity, biomarkers, internal validation
- MeSH terms
- Animals, Autoantibodies, Autoimmune Diseases, Enzyme-Linked Immunosorbent Assay, Humans, Immunoassay, Clinical Laboratory Techniques, Protein Array Analysis, Microfluidics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.